Regenxbio has completed dosing in a phase 1/2a clinical trial of its wet age-related macular degeneration treatment candidate, RGX-314, according to a press release.
The trial enrolled 42 subjects who were previously treated with anti-VEGF injections in five escalating dose cohorts. They each received a single subretinal dose of RGX-314.
“Patients with wet AMD require intravitreal injections every 4 to 12 weeks, on average, with the current standard of care,” Steve Pakola, MD, Regenxbio chief medical officer, said in the release. “We were pleased to report durable treatment